Diversity in Dermatology Clinical Trials

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1001/jamadermatol.2016.4129</td>
</tr>
<tr>
<td>Accessed</td>
<td>October 17, 2017 2:14:13 PM EDT</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:33785927">http://nrs.harvard.edu/urn-3:HUL.InstRepos:33785927</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>

(Article begins on next page)
The growth of the minority population in the United States is outpacing the growth of the non-Hispanic white population. Current projections estimate that the United States will achieve “majority-minority” status in which minority populations total over 50% of the overall population by 2044.¹

This demographic shift has not been reflected in medical research. African Americans, Hispanic individuals, and women are underrepresented in clinical² and randomized controlled trials generally,³ as well as within specific subspecialties including cancer clinical trials,⁴ pulmonary research,⁵ vascular surgery trials,⁶ and orthopedic research.⁷ General reporting of the racial and ethnic demographics of study cohorts is uncommon as well, with less than one-third of papers published in high-impact journals across all fields reporting racial or ethnic demographics.⁸

Federal efforts have targeted inclusion of clinical trial and research subjects at levels proportionate with those in the US population.⁹ The US Food and Drug Administration (FDA) currently requires that all investigational new drug and new drug applications studies include demographic information prior to approval.¹⁰ Additionally, National Institutes of Health (NIH)-funded clinical research studies must include women and minorities.¹¹ Despite a call to action to achieve diversity in research, that we know of there has been no systematic evaluation of clinical and research diversity among dermatology research subjects to date. Hirano et al¹² examined racial representation in atopic dermatitis research, demonstrating that only 60% of clinical trials of eczema and/or atopic dermatitis reported race.

This systematic review of the dermatology literature analyzed the degree of racial, ethnic, and sex representation in recent randomized clinical trials (RCTs) for acne, psoriasis, atopic dermatitis and eczema, vitiligo, alopecia areata, seborrheic dermatitis, and lichen planus (LP). These conditions were selected because they are:

**IMPORTANCE** Though there have been significant shifts in US demographic data over the past 50 years, research cohorts lack full racial and ethnic representation. There is little data available regarding the diversity of dermatology research cohorts with respect to sex, race, and ethnicity.

**OBJECTIVE** To characterize and assess the representation of racial and ethnic minorities and women in randomized controlled trials across a range of dermatologic conditions.

**EVIDENCE REVIEW** All randomized clinical trials (RCTs) were identified between July 2010 and July 2015 within the PubMed database using the following keywords: “psoriasis,” “atopic dermatitis,” “acne,” “vitiligo,” “seborrheic dermatitis,” “alopecia areata,” and “lichen planus.” Diverse study populations were defined as including a greater than 20% racial or ethnic minority participants based on US census data. The distributions of sex and race groups in studies were compared by journal type, disease type, and funding source.

**FINDINGS** Of the 626 articles reporting RCTs included in this analysis, 532 (85.0%) reported the sex of study participants. Overall, 52 of 626 international (11.3%) studies and 58 of 97 studies (59.8%) conducted exclusively within the United States reported on the racial or ethnic demographics of study participants. Across all RCTs exclusively recruited within the United States that reported race, 74.4% of study participants were white. Disease type was significantly associated with the degree of racial diversity (P < .001) within a study cohort: 30.0% of US-based psoriasi had more than 20% racially or ethnically diverse research participants as compared with 73.9% of acne studies and 91.7% of eczema studies.

**CONCLUSION AND RELEVANCE** Dermatologic clinical trials within the United States reflect the growing diversity of the US population. Reporting of both sex and racial/ethnic diversity of research cohorts is still lacking, especially among studies conducted outside of the United States.
(1) common, (2) lack specific racial predilection, and (3) well-studied. Nonmelanoma skin cancer, melanoma studies were not included in this review because of their disproportionate occurrence in white patients. Dyschromia and melasma were not included because of their disproportionate occurrence in patients with skin of color.

Methods

Search Strategy
A comprehensive systematic review of the literature was performed using the electronic database PubMed from the 5-year period between July 21, 2010, and July 21, 2015, for all peer-reviewed, English-language RCTs pertaining to acne, psoriasis, atopic dermatitis and eczema, vitiligo, lichen planus, alopecia areata, and seborrheic dermatitis. Search criteria were defined to include studies with the following key words: “lichen planus,” “psoriasis,” “atopic dermatitis,” “eczema,” “acne,” “seborrheic dermatitis,” “alopecia areata,” and “vitiligo” in the title, abstract, or body of potential search results. The titles and abstracts were reviewed prior to data abstraction; animal studies and studies of nondermatologic conditions were excluded. All data was obtained from publically available sources; institutional review board review was waived.

Race and Ethnicity Categorization
Race and ethnicity categorizations were defined using the constructs outlined by the Office of Management and Budget guidelines for federal data: American Indian or Alaskan Native, Asian, black or African American, Native Hawaiian or Other Pacific Islander, and white. Hispanic identity was recorded as a racial category in some articles and as an ethnicity in others. To reconcile this discrepancy, we recorded all participants who indicated they were of either of Hispanic ethnicity or Hispanic race as “Hispanic.” Individuals who indicated that they were any race other than white were considered nonwhite for bivariate analysis.

Data Abstraction
Each article title and abstract were reviewed and nondermatologic and animal-model papers were eliminated. The full text of all remaining articles was reviewed. Study data were collected and managed using REDCap (Research Electronic Data Capture) electronic data capture tools hosted through Partners Healthcare. Data was abstracted across the following domains: reporting of participant Fitzpatrick skin type, reporting of participant race, reporting of participant sex, and participant counts by sex and racial and/or ethnic demographic information. Any mention of demographic sex, race, and ethnicity was considered to be a report of such data, regardless of whether the data was reported in a study-subject table or the body of the paper.

We extracted year of publication, disease of concern, total number of patients, funding type (industry, foundation/nonprofit, government, none, or nonlisted), journal name, and journal type. Multiple papers from the same study or patient cohort were considered independently. The top 20% of articles (consisting of approximately 80% of the patients in this analysis) were independently validated by a second data abstractor to ensure accuracy and consistency.

Results

A total of 991 unique articles were identified. After elimination of 257 articles concerning nondermatologic conditions or conducted in nonhuman patients, elimination of duplicate articles (n = 10), non-RCTs (n = 89), and articles on diseases not included in our study (n = 9), 626 articles were ultimately included in the analysis. Of these, 97 studies were exclusively conducted in the United States and 164 were partially conducted in the United States (Figure 1).

Reporting of Race and Ethnicity
Race and ethnicity demographic data were included across at least 1 variable in 58 of 97 studies (59.8%) conducted exclusively in the United States and 97 of 164 studies (59.1%) conducted exclusively or partially in the United States (Figure 1); 52 of 462 studies (11.3%) that recruited outside of the United States recorded race or ethnicity. Information regarding whether race was self-reported was not reported in the vast majority of studies; a subanalysis of 53 studies revealed only 3 (5.7%) with reported data, all 3 of which were self-reported. Of the 58 studies recruited exclusively within the United States that reported data on race or ethnicity, 20 investigated psoriasis; 12, atopic dermatitis; 23, acne; 2, vitiligo; and 1, seborrheic dermatitis for a total of 13 681 study participants. None of the articles about lichen planus (n = 2 in United States) or alopecia areata (n = 1 in the United States) reported race or ethnicity.

Key Points

Question What is the racial, ethnic, and sex makeup of participants in randomized clinical trials of dermatologic conditions?

Findings In this systematic review of 626 trials conducted in 2010 through 2015, there was a low level of reporting of racial and ethnic composition of trial participants. Those US trials that reported race and ethnicity included a proportional number of women and African Americans compared with the general population, but Hispanic representation was lower than that of the general population of the United States.

Meaning While dermatologic clinical trials conducted in the United States are racially diverse, the field must increase reporting of race and ethnicity and strive for representative study cohorts especially with respect to ethnic diversity.

Statistical Analysis
Characteristics of included studies were presented as counts and percentages. Studies that reported race, ethnicity, and sex were categorized by their study participant distributions compared to the US population. We considered studies with less than 20% ethnically or racially diverse participants (defined as nonwhite race or Hispanic ethnicity) or less than 45% women to be underrepresentative of race/ethnicity, and sex, respectively. Counts and percentages of funding source, journal type, and disease type were presented overall and by level of race and ethnicity, and sex representation. The statistical significance of study differences by race and ethnicity, and sex representation was determined by χ² tests or Fisher exact tests as appropriate. Analyses were performed using SAS 9.4 (SAS Institute).

Downloaded From: http://jamanetwork.com/ by a Harvard University User on 08/17/2017
Funding source, journal type, and disease type were associated with the reporting of racial and ethnic data (P < .001 for all comparisons; Table 1). Articles containing research funded by industry (n = 116 [42.3%]) were more likely to report race and ethnicity than research funded by other entities (P < .001 for all comparisons). Studies in dermatology pharmacology journals (n = 29 [50.9%]) were most likely to report race and ethnicity (P < .001).

A subgroup analysis of trials conducted exclusively in the United States (n = 97) demonstrated a correlation between disease type and reporting of race/ethnicity; with vitiligo (n = 2 [100%]) and psoriasis (n = 20 [76.9%]) studies more likely to report than acne (n = 23 [54.8%]) and eczema (n = 12 [52.5%]) (P < .001 for all comparisons).

Racial Composition of Trials

Overall, among the 58 studies conducted exclusively within the United States that recorded race/ethnicity, 10 177 of 13 681 (74.4%) study participants were white. Among these studies, 46 (79.3%) noted racial categories other than white and nonwhite for a total of 11 140 participants; of these, 8016 (72.0%) of study participants were white, 1446 (13.0%) were African American, 1639 (14.7%) were recorded as Hispanic, and 370 (3.3%) were recorded as Asian; 331 of these 11 140 participants identified themselves as ethnically Hispanic and racially as nonwhite and were thus counted within the totals of both groups. Articles about eczema (n = 11 [91.7%]) and acne studies (n = 17 [73.9%]) were more likely to include more than 20% racially/ethnically diverse participants than psoriasis studies (P < .001) (Table 1). Psoriasis studies included the least diversity with 84.3% of total study participants recorded as white. Funding source and journal type did not demonstrate a statistically significant relationship with respect to the diversity of study subjects (P = .70 and P = .21, respectively [Table 1]).

Reporting and Distribution of Sex

A total of 532 articles (85.0%) included data on the number of male and women participants. The majority of participants (68 760 of 125 266 [54.9%]) were women. General medicine (n = 20 [87.0%]) and dermatology journals (n = 346 [87.2%]) were more likely to report sex distribution than other journal types (P = .03) (Table 2).

Disease type, funding source, and journal type all demonstrated a statistically significant relationship to the proportion of women participants within a given study (P ≤ .01 across all comparisons; Figure 2). Articles funded by industry (n = 175 [75.1%]) were more likely to have more than 45% women when compared with those supported by other sources (P < .001). Psoriasis studies were overrepresentative of women, as 87.2% of reporting studies had greater than 45% women, and 42 190 of 65 984 participants (63.9%) were women (Table 2).

Discussion

Our analysis of randomized clinical trials in dermatology in acne, vitiligo, and atopic dermatitis over the past 5 years demonstrates a diverse racial and ethnic representation and roughly equal representation of sex. This contrasts with other medical specialties where full racial representation lags. However, representation of Hispanics and other minorities were still somewhat lacking. While those trials that fully characterized race achieved recruitment of a proportional number of African American participants (compared with the US population at 13%), those same trials did not achieve such proportionality with respect to ethnicity. Although 17% of the population identifies as Hispanic by ethnicity, only 14.7% of participants in those same studies identified ethnically as Hispanic. Moreover, the dearth of full reporting of ethnicity and race suggests that the actual racial and ethnic makeup of many studies may be decidedly more homogenous.

Dermatologic research seems to be achieving racial diversity in most clinical trials where such data are reported, but the low rate of full reporting and the lower-than-proportional representation of Hispanic individuals requires greater attention. Significant health disparities exist between whites and racial/ethnic minorities. Diversity research cohorts are needed to demonstrate the potential disparities in treatment of dermatologic diseases, and investigate effective treatments. Assuring this racial/ethnic and sex diversity will help advance clinical medicine while promoting patient equity. To that end, dermatology trials need to improve their reporting of demographic data. Only 59.8% of papers conducted exclusively within the United States reported the racial demographics of their study participants despite the ease with which such data can be collected and reported. Although low, the US reporting is substantially higher than reporting among non-US studies (11.3% reporting of race or ethnicity). This may represent unique demographic differences between the United States and Europe or the influence of targeted diversity policy on research in the United States including the National Institutes of Health (NIH) Revitalization Act of 1993 and additional guidelines put in place by NIH in 2000.
Table 1. Publication Characteristics by Race Reporting for Dermatology RCTs

<table>
<thead>
<tr>
<th>Publication Characteristics</th>
<th>No. of All RCTs</th>
<th>RCT Reported Race/Ethnicity, No. (%)</th>
<th>Exclusively US RCTs, No. (%)</th>
<th>RCT Reported Race/Ethnicity, ≥20% Nonwhite Representation, No. (%)</th>
<th>P Value&lt;sup&gt;a&lt;/sup&gt;</th>
<th>P Value&lt;sup&gt;a&lt;/sup&gt;</th>
<th>P Value&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>626</td>
<td>149 (23.8)</td>
<td>97</td>
<td>58 (59.8)</td>
<td>.03</td>
<td>.70</td>
<td></td>
</tr>
<tr>
<td>Funding</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Government</td>
<td>48</td>
<td>7 (14.6)</td>
<td>5</td>
<td>5 (100)</td>
<td>.001</td>
<td>.03</td>
<td>.40</td>
</tr>
<tr>
<td>Industry</td>
<td>274</td>
<td>116 (42.3)</td>
<td>66</td>
<td>41 (62.1)</td>
<td></td>
<td></td>
<td>.58</td>
</tr>
<tr>
<td>Government/industry mix</td>
<td>8</td>
<td>1 (12.5)</td>
<td>0</td>
<td>NA</td>
<td></td>
<td></td>
<td>NA</td>
</tr>
<tr>
<td>Nonprofit</td>
<td>64</td>
<td>7 (10.9)</td>
<td>9</td>
<td>2 (22.2)</td>
<td></td>
<td></td>
<td>.10</td>
</tr>
<tr>
<td>No funding</td>
<td>43</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
<td>NA</td>
</tr>
<tr>
<td>Funding not specified</td>
<td>189</td>
<td>18 (9.5)</td>
<td>16</td>
<td>10 (62.5)</td>
<td>&lt;.001</td>
<td>.06</td>
<td>.001</td>
</tr>
<tr>
<td>Disease type</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psoriasis</td>
<td>216</td>
<td>77 (35.6)</td>
<td>26</td>
<td>20 (76.9)</td>
<td></td>
<td></td>
<td>6 (30.0)</td>
</tr>
<tr>
<td>Eczema</td>
<td>181</td>
<td>28 (15.5)</td>
<td>23</td>
<td>12 (52.2)</td>
<td></td>
<td></td>
<td>11 (91.7)</td>
</tr>
<tr>
<td>Acne</td>
<td>144</td>
<td>35 (24.3)</td>
<td>42</td>
<td>23 (54.8)</td>
<td></td>
<td></td>
<td>17 (73.9)</td>
</tr>
<tr>
<td>Lichen planus</td>
<td>25</td>
<td>1 (4.0)</td>
<td>2</td>
<td>0</td>
<td></td>
<td></td>
<td>NA</td>
</tr>
<tr>
<td>Vitiligo</td>
<td>36</td>
<td>4 (11.1)</td>
<td>2</td>
<td>2 (100)</td>
<td></td>
<td></td>
<td>2 (100)</td>
</tr>
<tr>
<td>Alopecia areata</td>
<td>8</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td></td>
<td></td>
<td>NA</td>
</tr>
<tr>
<td>Seborrheic dermatitis</td>
<td>16</td>
<td>4 (25.0)</td>
<td>1</td>
<td>1 (100)</td>
<td></td>
<td></td>
<td>1 (100)</td>
</tr>
<tr>
<td>Journal type</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;.001</td>
<td>.62</td>
<td>.21</td>
</tr>
<tr>
<td>Dermatology</td>
<td>397</td>
<td>93 (23.4)</td>
<td>53</td>
<td>33 (62.3)</td>
<td></td>
<td></td>
<td>22 (66.7)</td>
</tr>
<tr>
<td>General medicine</td>
<td>23</td>
<td>6 (26.1)</td>
<td>0</td>
<td>NA</td>
<td></td>
<td></td>
<td>NA</td>
</tr>
<tr>
<td>Dermatology pharmacology</td>
<td>57</td>
<td>29 (50.9)</td>
<td>33</td>
<td>18 (54.5)</td>
<td></td>
<td></td>
<td>13 (72.2)</td>
</tr>
<tr>
<td>General pharmacology</td>
<td>13</td>
<td>2 (15.4)</td>
<td>1</td>
<td>1 (100)</td>
<td></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>Allergy</td>
<td>45</td>
<td>6 (13.3)</td>
<td>5</td>
<td>2 (40.0)</td>
<td></td>
<td></td>
<td>1 (50.0)</td>
</tr>
<tr>
<td>Other/undetermined</td>
<td>91</td>
<td>13 (14.3)</td>
<td>5</td>
<td>4 (80.0)</td>
<td></td>
<td></td>
<td>1 (25.0)</td>
</tr>
</tbody>
</table>

Abbreviations: NA, not applicable; RCT, randomized clinical trial.

<sup>a</sup> P values from χ<sup>2</sup> or Fisher exact tests as appropriate.

<sup>b</sup> The percent is calculated among studies conducted exclusively in the US that report race.

Table 2. Publication Characteristics by Sex Reporting for Dermatology RCTs

<table>
<thead>
<tr>
<th>Publication Characteristics</th>
<th>No. of All RCTs</th>
<th>RCT Reported Sex, No. (%)</th>
<th>≥45% Women Representation, No. (%)</th>
<th>P Value&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>626</td>
<td>532 (85.0)</td>
<td>349 (65.6)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Funding</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Government</td>
<td>48</td>
<td>38 (79.2)</td>
<td>21 (55.3)</td>
<td>.65</td>
</tr>
<tr>
<td>Industry</td>
<td>274</td>
<td>231 (85.0)</td>
<td>175 (75.1)</td>
<td>.01</td>
</tr>
<tr>
<td>Government/industry mix</td>
<td>8</td>
<td>6 (75.0)</td>
<td>4 (66.7)</td>
<td></td>
</tr>
<tr>
<td>Nonprofit</td>
<td>64</td>
<td>56 (87.5)</td>
<td>28 (50.0)</td>
<td></td>
</tr>
<tr>
<td>No funding</td>
<td>43</td>
<td>39 (90.7)</td>
<td>28 (71.8)</td>
<td></td>
</tr>
<tr>
<td>Funding not specified</td>
<td>189</td>
<td>160 (84.7)</td>
<td>93 (58.1)</td>
<td></td>
</tr>
<tr>
<td>Disease type</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psoriasis</td>
<td>216</td>
<td>188 (87.0)</td>
<td>164 (87.2)</td>
<td>.27</td>
</tr>
<tr>
<td>Eczema</td>
<td>181</td>
<td>147 (81.2)</td>
<td>102 (69.4)</td>
<td></td>
</tr>
<tr>
<td>Acne</td>
<td>144</td>
<td>124 (86.1)</td>
<td>51 (41.1)</td>
<td></td>
</tr>
<tr>
<td>Lichen planus</td>
<td>25</td>
<td>19 (76.0)</td>
<td>5 (26.3)</td>
<td></td>
</tr>
<tr>
<td>Vitiligo</td>
<td>36</td>
<td>31 (86.1)</td>
<td>12 (38.7)</td>
<td></td>
</tr>
<tr>
<td>Alopecia areata</td>
<td>8</td>
<td>7 (87.5)</td>
<td>4 (57.1)</td>
<td></td>
</tr>
<tr>
<td>Seborrheic dermatitis</td>
<td>16</td>
<td>16 (100)</td>
<td>11 (68.8)</td>
<td></td>
</tr>
<tr>
<td>Journal type</td>
<td></td>
<td></td>
<td></td>
<td>.03</td>
</tr>
<tr>
<td>Dermatology</td>
<td>397</td>
<td>346 (87.2)</td>
<td>219 (63.3)</td>
<td>.004</td>
</tr>
<tr>
<td>General medicine</td>
<td>23</td>
<td>20 (87.0)</td>
<td>16 (80.0)</td>
<td></td>
</tr>
<tr>
<td>Dermatology pharmacology</td>
<td>57</td>
<td>41 (71.9)</td>
<td>28 (68.3)</td>
<td></td>
</tr>
<tr>
<td>General pharmacology</td>
<td>13</td>
<td>9 (69.2)</td>
<td>9 (100)</td>
<td></td>
</tr>
<tr>
<td>Allergy</td>
<td>45</td>
<td>37 (82.2)</td>
<td>32 (86.5)</td>
<td></td>
</tr>
<tr>
<td>Other/undetermined</td>
<td>91</td>
<td>79 (86.8)</td>
<td>45 (57.0)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: RCT, randomized clinical trial.

<sup>a</sup> P values from Fisher exact tests.

<sup>b</sup> The percent is calculated among studies that report sex.
cohort. Racial and perhaps to a greater extent, ethnic diversity in research will continue to be critical for ensuring all individuals have access to new treatment. However, a focus on characterizing and promoting genetic variability among study participants is required for determining biological differences in drug response and metabolism.

Our findings must be interpreted in the context of the study design. We chose to analyze specific disease states as opposed to including all dermatologic conditions across the literature. In limiting our study to specific conditions, we did not include studies of less common diseases. Common diseases that lack a strong racial propensity and are studied readily in the literature were selected. However, some variation in patient population may be explained by baseline differences in prevalence of these diseases between various races and ethnicities.

The categorization of ethnically Hispanic study participants differed across articles. Some articles characterized Hispanic individuals as ethnically Hispanic and others characterized them as racially Hispanic. In our analysis all Hispanic participants were considered ethnically Hispanic, and cohorts that were either racially or ethnically diverse were classified as diverse. Although this characterization is not ideal, most papers did not include specific racial information on Hispanic study participants, and our study is limited in its ability to fully classify the diversity of such participants and their respective cohorts. Because we cannot consistently subclassify patients of Hispanic ethnicity by race (eg, white, black), our study may be more likely to characterize a study’s cohort as diverse. The dearth of data on study participant ethnicity reinforces the need for more detailed reporting of race and ethnicity within the dermatologic.

Conclusions

Dermatology is a field uniquely positioned to focus its attention on diversity within clinical practice and research. This study demonstrates that while dermatology researchers recruit diverse participant cohorts, our ability to fully understand the composition of patients in dermatology clinical trials is limited by the number of studies that fail to report the racial and ethnic demographics of their participants. Moreover, there is still work to be done in characterizing ethnicity with respect to Hispanic participants. Journals and funding sources can reinforce our diverse clinical trial population by continuing to prioritize racial, ethnic, and genetic diversity within the articles they fund and publish; requiring reporting of racial and ethnic data in all dermatology RCTs will lead us even further. These combined efforts will enable dermatology to be an example within medicine for how to best achieve diversity within research and, by extension, clinical practice.

References


2. Geller SE, Adams MG, Carnes M. Adherence to federal guidelines for reporting of sex and ethnicity. JAMA Dermatology February 2017 Volume 153, Number 2 197
race/ethnicity in clinical trials. J Women’s Health
3. Rochon PA, Mashari A, Cohen A, et al. The
inclusion of minority groups in clinical trials:
problems of underrepresentation and under
4. Murthy VH, Krumholz HM, Gross CP.
Participation in cancer clinical trials: race, sex,
and age-based disparities. JAMA. 2004;291(22):2720-
2726.
5. Burchard EG, Oh SS, Foreman MG, Celedón JC.
Moving toward true inclusion of racial/ethnic
minorities in federally funded studies: a key step for
achieving respiratory health equality in the United
6. Hoel AW, Kayssl A, Brahmanandam S, Bellin M,
Conte MS, Nguyen LL. Under-representation of
women and ethnic minorities in vascular surgery
349-354.
7. Somerson JS, Bhandari M, Vaughan CT, Smith
CS, Zelle BA. Lack of diversity in orthopaedic trials
2014;96(7):e56.
8. Rochon PA, Mashari A, Cohen A, et al. The
inclusion of minority groups in clinical trials:
problems of underrepresentation and under
9. Reardon S. US Tailored-medicine project aims
/news/us-tailored-medicine-project-aims-for-ethnic-
variety-1.88023?WT.mc_id=TWT
Guidance for Industry: Collection of Race and
Ethnicity Data in Clinical Trials. http://www.fda.gov/
downloads/regulatoryinformation/guidances
11. Public Law 103-43. National Institutes of Health
.govtrack.us/congress/bills/103/s1. Accessed
September 10, 2015.
12. Hirano SA, Murray SB, Harvey VM. Reporting,
representation, and subgroup analysis of race and
ethnicity in published clinical trials of atopic
dermatitis in the United States between 2000 and
13. Wysong A, Linos E, Hernandez-Boussard T,
Arron ST, Gladstone H, Tang JY. Nonmelanoma skin
cancer visits and procedure patterns in a nationally
representative sample: national ambulatory
N, Conde JG. Research electronic data capture
(REDCap)—a metadata-driven methodology and
workflow process for providing translational
2009;42(2):377-381.
15. Geller SE, Adams MG, Carnes M. Adherence to
federal guidelines for reporting of sex and
race/ethnicity in clinical trials. J Women’s Health
inclusion of minority groups in clinical trials:
problems of underrepresentation and under
17. Oh SS, Galanter J, Thakur N, et al. Diversity in
Clinical and Biomedical Research: A promise yet to
18. US Congress. National Institutes of Health
Revitalization Act of DC. Act to Amend the Public
Health Service Act to Revise and Extend the Programs
of the National Institutes of Health, and for Other
Purpose. Public Law Washington, Washington, DC.
1993:103-143.
19. National Institutes of Health. NIH Guideline on
the Inclusion of Women and Minorities as Subjects in
https://grants.nih.gov/grants/funding/women_min
20. Serre D, Pääbo S. Evidence for gradients of
human genetic diversity within and among
21. Ng PC, Zhao Q, Levy S, Strausberg RL, Venter
JC. Individual genomes instead of race for
84(3):306-309.
22. Yudell M, Roberts D, DeSalle R, Tishkoff S.
Science and society: taking race out of human
23. Chung WH, Hung SJ, Hong HS, et al. Medical
genetics, a marker for Stevens-Johnson syndrome.
Underlying genetic structure impacts the
association between CYP2B6 polymorphisms and
response to efavirenz and nevirapine. AIDs.
Consortium. Genome-wide association study of breast
cancer in Latinas identifies novel protective variants on